Korean J Perinatol.  2015 Mar;26(1):28-34. 10.14734/kjp.2015.26.1.28.

Maternal Plasma Angiopoietin-1 and Angiopoietin-2 in Pregnant Women with Chronic Hypertension

• Kim E
• Kang M
• Jun JK

• KMID: 2072334
• DOI: http://doi.org/10.14734/kjp.2015.26.1.28

Abstract

PURPOSE
The aim of this study was to investigate whether plasma angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) concentrations in pregnant women with chronic hypertension are different from those of normotensive pregnant women.
METHODS
This hospital-based case-control study consisted of 35 pregnant women with chronic hypertension who delivered at Seoul National University Hospital. Normotensive pregnant women (n=70) were selected as controls, matched with maternal age, gestational age at delivery and birthweight. Maternal blood was drawn at the time of admission for delivery and plasma was separated and stored. The plasma Ang-1 and Ang-2 levels were measured by ELISA. Statistical analysis was done with Mann-Whitney U test, Fisher's exact test and Spearman rank correlation test using SPSS.
RESULTS
Median (range) maternal age, gestational age and birthweight were 33 years (24-42), 38 weeks (32-41), and 3.08 kg (1.13-4.01). Pregnant women with chronic hypertension had significantly higher median Ang-1 and Ang-2 levels than normotensive pregnant women (for Ang-1 : median 4,111 pg/mL, range 1,415-30,172 vs. median 2,824 pg/mL range 662-14,512, P=0.015, for Ang-2 : median 5,637 pg/mL, range 1,131-29,327 vs. median 3,345 pg/mL, range 609-24,467, P=0.039).
CONCLUSION
Maternal plasma Ang-1 and Ang-2 levels were elevated in pregnant women with chronic hypertension compared with normotensive pregnant women. Further study is needed to determine if this change is a cause or a compensatory mechanism to chronic hypertension.

Keyword

Chronic hypertension; Angiopoietin; Vasculogenesis; Angiogenesis

MeSH Terms

Angiopoietin-1*
Angiopoietin-2*
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Female
Gestational Age
Humans
Hypertension*
Maternal Age
Plasma*
Pregnant Women*
Seoul
Angiopoietin-1
Angiopoietin-2

Reference

References

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003; 290:199–206.

2. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998; 338:701–5.

3. Yanit KE, Snowden JM, Cheng YW, Caughey AB. The impact of chronic hypertension and pregestatioanal diabetes in pregnancy outcome. Am J Obstet Gynecol. 2012; 207:333. e1–6.

4. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277:55–60.

5. Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B, et al. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol. 2000; 156:2185–99.

6. Papapetropoulos A, García-Cardeña G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999; 79:213–23.

7. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284:1994–8.

8. ACOG Committee on Practice Bulletins–Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002; 99:159–67.

9. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost. 2005; 94:1071–6.

10. Shroff RC, Price KL, Kolatsi-Joannou M, Todd AF, Wells D, Deanfield J, et al. Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis. PLoS One. 2013; 8:e56273.

11. Shim SS, Lee CH, Jun JK. Midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor in pregnant women who subsequently develop preeclampsia. Obstet Gynecol Sci. 2015; 58:10–6.

12. Khalil A, Maiz N, Garcia-Mandujano R, Elkhouli M, Nicolaides KH. Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for preeclampsia. Ultrasound Obstet Gynecol. 2014; 44:402–10.

13. Han SY, Jun JK, Lee CH, Park JS, Syn HC. Angiopoietin-2: a promising indicator for the occurrence of severe preeclampsia. Hypertens Pregnancy. 2012; 31:189–99.

14. Leinonen E, Wathen KA, Alfthan H, Ylikorkala O, Andersson S, Stenman UH, et al. Maternal serum angio-poietin-1 and −2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2010; 95:126–33.

15. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, et al. Increase of serum angio-poietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens. 2005; 18:1181–8.

16. Polyzou EN, Evangelinakis NE, Pistiki A, Kotsaki A, Siristatidis CS, Chrelias CG, et al. Angiopoietin-2 primes infection-induced preterm delivery. PLoS One. 2014; 9:e86523.

17. Schneuer FJ, Roberts CL, Ashton AW, Guilbert C, Tasevski V, Morris JM. Angiopoietin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes. Am J Obstet Gynecol. 2014; 210:345.e1–9.